EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Adjunctive Resveratrol or Omeprazole in Patients with Non-Transfusion-Dependent Thalassemia with Iron Overload: A Randomized, Double-Blind, Placebo-Controlled Trial

Thanapong Chopetgool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong iD, Lalita Norasetthada iD, Thanawat Rattanathammethee iD, Sasinee Hantrakool iD, Pokpong Piriyakhuntorn, Teerachat Punnachat iD, Nonthakorn Hantrakun, Sirichai Srichairatanakool, Pimpisid Koonyosying iD, Somdet Srichairatanakool iD und 1 weitere

International Journal of Molecular Sciences · 06.11.2026 · 27 (21) · 9939

DOI: 10.3390/ijms27219939 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.11.2026. Verfasst von Thanapong Chopetgool und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Hauptthemen laut MEDLINE: Iron Overload, Resveratrol, Omeprazole, Thalassemia. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiang Mai University, National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased gastrointestinal iron absorption contributes substantially to iron overload in non-transfusion-dependent thalassemia (NTDT) patients. Resveratrol (RVT) and omeprazole (OMP) may reduce intestinal iron absorption and potentially complement iron chelation therapy. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of adjunctive RVT or OMP in adults with NTDT receiving stable iron chelation therapy. The primary outcome was the change in serum ferritin; secondary outcomes influenced serum iron (SI), transferrin saturation (TS), erythroferrone (ERFE), hepcidin, fetal hemoglobin (HbF), and safety. Participants with serum ferritin ≥ 300 ng/mL were randomized (1:1:1) to receive RVT 250 mg, OMP 20 mg, or the placebo (PLA) twice daily for 6 months. Thirty participants were randomized (RVT, n = 10; OMP, n = 11; PLA, n = 9), with a baseline median serum ferritin value of 629 ng/mL, interquartile range (IQR) 484–975. Serum ferritin decreased numerically over 6 months in the RVT and OMP groups relative to PLA; however, no significant treatment × time interactions or adjusted between-group differences in changes from the baseline were observed. Although significant within-group changes were observed for selected iron-regulatory biomarkers, including hepcidin, ERFE, and TS, these were not accompanied by significant treatment × time interactions and did not demonstrate differential treatment effects. Both interventions were generally well tolerated, and no serious adverse events were reported. In this underpowered trial, neither adjunctive RVT nor OMP demonstrated statistically significant treatment-specific effects on serum ferritin or other iron-related outcomes when compared with the placebo. The observed numerical trends warrant evaluation in larger, adequately powered trials. Trial Registration: ISRCTN73258526.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iron OverloadResveratrolOmeprazoleThalassemiaHumansDouble-Blind MethodFerritinsFemaleAdultMaleHepcidinsIronTreatment OutcomeIron Chelating Agents

Stichwörter der Autor:innen

NTDThepcidiniron overloadnon-transfusion-dependent thalassemiaomeprazoleresveratrolthalassemia

Substanzen

ResveratrolOmeprazoleFerritinsHepcidinsIronIron Chelating Agents

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

ORCID-Profile: Ekarat Rattarittamrong, Lalita Norasetthada, Thanawat Rattanathammethee, Sasinee Hantrakool, Teerachat Punnachat, Pimpisid Koonyosying, Somdet Srichairatanakool, Adisak Tantiworawit

Förderung

  • Chiang Mai University
  • National Research Council of Thailand

Zitieren

APA

Chopetgool, T., Chai-Adisaksopha, C., Rattarittamrong, E., Norasetthada, L., Rattanathammethee, T., Hantrakool, S., Piriyakhuntorn, P., Punnachat, T., Hantrakun, N., Srichairatanakool, S., Koonyosying, P., Srichairatanakool, S., & Tantiworawit, A. (2026). Adjunctive Resveratrol or Omeprazole in Patients with Non-Transfusion-Dependent Thalassemia with Iron Overload: A Randomized, Double-Blind, Placebo-Controlled Trial. International Journal of Molecular Sciences, 27(21), 9939. https://doi.org/10.3390/ijms27219939

Vancouver

Chopetgool T, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, Rattanathammethee T, Hantrakool S, et al. Adjunctive Resveratrol or Omeprazole in Patients with Non-Transfusion-Dependent Thalassemia with Iron Overload: A Randomized, Double-Blind, Placebo-Controlled Trial. International Journal of Molecular Sciences. 2026;27(21):9939. doi:10.3390/ijms27219939

BibTeX
@article{Chopetgool2026,
  author = {Chopetgool, Thanapong and Chai-Adisaksopha, Chatree and Rattarittamrong, Ekarat and Norasetthada, Lalita and Rattanathammethee, Thanawat and Hantrakool, Sasinee and Piriyakhuntorn, Pokpong and Punnachat, Teerachat and Hantrakun, Nonthakorn and Srichairatanakool, Sirichai and Koonyosying, Pimpisid and Srichairatanakool, Somdet and Tantiworawit, Adisak},
  title = {Adjunctive Resveratrol or Omeprazole in Patients with Non-Transfusion-Dependent Thalassemia with Iron Overload: A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9939},
  doi = {10.3390/ijms27219939}
}
Kostenlos starten →